AU1333699A - Use of heparin-binding protein for the modulation or prophylaxis of apoptosis ofmammalian cells - Google Patents

Use of heparin-binding protein for the modulation or prophylaxis of apoptosis ofmammalian cells

Info

Publication number
AU1333699A
AU1333699A AU13336/99A AU1333699A AU1333699A AU 1333699 A AU1333699 A AU 1333699A AU 13336/99 A AU13336/99 A AU 13336/99A AU 1333699 A AU1333699 A AU 1333699A AU 1333699 A AU1333699 A AU 1333699A
Authority
AU
Australia
Prior art keywords
ofmammalian
prophylaxis
heparin
apoptosis
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13336/99A
Inventor
Hans Jakob Flodgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU1333699A publication Critical patent/AU1333699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU13336/99A 1997-11-20 1998-11-20 Use of heparin-binding protein for the modulation or prophylaxis of apoptosis ofmammalian cells Abandoned AU1333699A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK132497 1997-11-20
DK1324/97 1997-11-20
DK139497 1997-12-03
DK1394/97 1997-12-03
PCT/DK1998/000510 WO1999026647A1 (en) 1997-11-20 1998-11-20 Use of heparin-binding protein for the modulation or prophylaxis of apoptosis of mammalian cells

Publications (1)

Publication Number Publication Date
AU1333699A true AU1333699A (en) 1999-06-15

Family

ID=26065587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13336/99A Abandoned AU1333699A (en) 1997-11-20 1998-11-20 Use of heparin-binding protein for the modulation or prophylaxis of apoptosis ofmammalian cells

Country Status (4)

Country Link
EP (1) EP1032412A1 (en)
JP (1) JP2002505252A (en)
AU (1) AU1333699A (en)
WO (1) WO1999026647A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026352A1 (en) * 1998-11-04 2000-05-11 Chugai Research Institute For Molecular Medicine, Inc. Novel trypsin family serine proteases
US7217554B2 (en) 1999-08-31 2007-05-15 Novozymes A/S Proteases and variants thereof
NZ531394A (en) 1999-08-31 2005-10-28 Novozymes As Residual protease II (RPII) and variants thereof useful in detergent compositions
WO2003080660A2 (en) * 2002-03-27 2003-10-02 Leukotech A/S Method for the preparation of recombinant mammalian heparin-binding protein (hbp)
EP4028012A1 (en) * 2019-09-09 2022-07-20 Christian-Albrechts-Universität zu Kiel Compound for inhibiting cell death

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028544A1 (en) * 1995-03-09 1996-09-19 Novo Nordisk A/S A protein-lipid conjugate, consisting of heparin binding protein (hbp) and a ceramide analogue, and its pharmaceutical use in treatment of conditions involving stress injury to cells

Also Published As

Publication number Publication date
EP1032412A1 (en) 2000-09-06
JP2002505252A (en) 2002-02-19
WO1999026647A1 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU2434199A (en) Protein
AU6042298A (en) Tissue factor pathway inhibitor-3
AU7069198A (en) Collimator
AU4184299A (en) Human apoptosis associated proteins
AU6882598A (en) Protein kinase inhibitor
AU6143998A (en) Regulators of apoptosis
AU4944297A (en) Modulation of apoptosis
AUPO561697A0 (en) Haemocompatible surfaces
AU4021797A (en) Sulfonamides
AU4930399A (en) Novel Polypeptide
AU1333699A (en) Use of heparin-binding protein for the modulation or prophylaxis of apoptosis ofmammalian cells
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU2591299A (en) Human protein kinase c inhibitor
AU5446499A (en) Apoptosis inducing agents
AU2659600A (en) Adipose specific protein
AU6275098A (en) Novel h-rev 107-like protein
AU2538899A (en) Protein kinase c
AU5467099A (en) Novel apoptosis proteins
AU1184800A (en) Novel polypeptide
AU5278199A (en) Protein for regulating apoptosis
AU4438599A (en) Human arf-related proteins
AU6947298A (en) Modulating the rad-nm23 interaction
AU6668798A (en) Novel microtubule-associated protein
AU5680898A (en) Sulfonamide derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase